Compare LXEO & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LXEO | BRBI |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Brazil |
| Employees | 59 | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 293.2M |
| IPO Year | 2023 | 2025 |
| Metric | LXEO | BRBI |
|---|---|---|
| Price | $4.28 | $11.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 679.5K | 930.0 |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.03% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.24 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $9.09 |
| 52 Week High | $10.99 | $67.01 |
| Indicator | LXEO | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 53.80 |
| Support Level | $4.01 | $10.90 |
| Resistance Level | $5.38 | $11.97 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.06 | 0.28 |
| Stochastic Oscillator | 5.59 | 94.34 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.